Reviva Pharmaceuticals

58 articles about Reviva Pharmaceuticals

• Reviva Pharmaceuticals Announced Preclinical Efficacy Data on Brilaroxazine in IPF at the 2023 American Thoracic Society International Conference and Publication in Medical Research Archives

  5/25/2023

  Reviva Pharmaceuticals Holdings, Inc. has presented preclinical data on the novel serotonin-dopamine modulator brilaroxazine in idiopathic pulmonary fibrosis at the 2023 American Thoracic Society International Conference which took place in Washington, DC, USA, May 19-24, 2023.

• Reviva Pharmaceuticals Announces Presentation of Clinical Pharmacology Studies Data on Brilaroxazine at the ASPET 2023 Annual Meeting

  5/22/2023

  Reviva Pharmaceuticals Holdings, Inc. has presented two posters on promising clinical pharmacology and safety studies data on the novel serotonin-dopamine stabilizer brilaroxazine at the American Society for Pharmacology and Experimental Therapeutics 2023 annual meeting took place in St.

• Reviva Pharmaceuticals Joins Webull Corporate Communications Service Platform

  5/19/2023

  Reviva Pharmaceuticals Holdings, Inc. announced the Company has joined Webull’s Corporate Communications Service Platform.

• Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in May 2023

  5/18/2023

  Reviva Pharmaceuticals Holdings, Inc. announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting at two upcoming investor conferences to be held in May 2023.

• Reviva Reports First Quarter 2023 Financial Results and Recent Business Highlights

  5/15/2023

  Reviva Pharmaceuticals Holdings, Inc. today reported financial results for the first quarter ended March 31, 2023 and summarized recent business highlights.

• Reviva Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference

  5/12/2023

  Reviva Pharmaceuticals Holdings, Inc. announced that it will be participating in the Lytham Partners Spring 2023 Investor Conference taking place virtually on Thursday, May 18, 2023.

• Reviva Pharmaceuticals Announces Intent to File an IND for Brilaroxazine in Psoriasis After Promising Preclinical Data

  5/11/2023

  Reviva Pharmaceuticals Holdings, Inc. has presented promising preclinical data on the potential of novel serotonin-dopamine stabilizer brilaroxazine for the treatment of psoriasis at the First International Societies for Investigative Dermatology Meeting in Tokyo, Japan, May 10-13, 2023.

• Reviva Pharmaceuticals to Present at Three Upcoming Scientific Conferences in May 2023

  5/4/2023

  Reviva Pharmaceuticals Holdings, Inc. announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting at three upcoming scientific conferences to be held in May 2023.

• Reviva Pharmaceuticals Presented Foundational Preclinical Data on Novel Serotonin-Dopamine Stabilizer Brilaroxazine at the 78th Annual SOBP and Publication in Medical Research Archives

  5/1/2023

  Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”) has presented the foundational preclinical data that supported the initial clinical development of its novel serotonin-dopamine stabilizer brilaroxazine at the 78th Annual Scientific Convention of the Society of Biological Psychiatry (SOBP) in San Diego.

• Reviva Pharmaceuticals to Host Key Opinion Leader Event on Brilaroxazine (RP5063) in Phase 3 Clinical Trials for Schizophrenia

  4/25/2023

  Reviva Pharmaceuticals Holdings, Inc. today announced it will host a KOL webinar on brilaroxazine (RP5063), a serotonin-dopamine modulator in late-stage development for schizophrenia, on May 2 nd at 11:00am ET.

• Reviva Pharmaceuticals to Present on Novel Serotonin-Dopamine Stabilizer Brilaroxazine at the 78th Annual Scientific Convention of the Society of Biological Psychiatry

  4/20/2023

  Reviva Pharmaceuticals Holdings, Inc. announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting a poster at the 78th Annual Scientific Convention of the Society of Biological Psychiatry, to be held in San Diego, CA April 27-29, 2023.

• Reviva Pharmaceuticals Holdings, Inc. Reports Full Year 2022 Financial Results and Recent Business Highlights

  3/30/2023

  Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”) today reported financial results for the full year ended December 31, 2022 and summarized recent business highlights.

• Reviva Pharmaceuticals to Present at the 35th Annual Roth Conference

  3/7/2023

  Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”) today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the 35th Annual Roth Conference, taking place March 12-14 in Dana Point, CA.

• Reviva Pharmaceuticals to Present at the 2023 BIO CEO and Investor Conference

  1/31/2023

  Reviva Pharmaceuticals Holdings, Inc. today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the BIO CEO and Investor Conference being held February 6–9, 2023.

• Reviva Pharmaceuticals Announces Letter to Shareholders

  1/4/2023

  Reviva Pharmaceuticals Holdings, Inc. is pleased to announce a letter to shareholders from Founder, President, and CEO, Laxminarayan Bhat, Ph.D. The full text of the letter follows.

• Reviva Pharmaceuticals Announces Positive Safety Data from Drug-Drug Interaction Clinical Study of Brilaroxazine

  12/15/2022

  Reviva Pharmaceuticals Holdings, Inc. today announced positive data from its recently completed clinical drug-drug interaction (DDI) study investigating the potential effect of CYP3A4 enzyme on brilaroxazine in healthy subjects.

• Reviva Pharmaceuticals Announces Canadian Composition of Matter Patent for Triple Reuptake Inhibitor RP1208

  11/21/2022

  Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”) today announced the issuance of a patent covering composition of matter for RP1208 in Canada, adding to its existing protection in key markets around the world. The Canadian patent covers the compositions of novel phenylcycloalkylmethylamine derivatives and the use of the compositions for the treatment of obesity, and related co-morbid conditions and depression and related co-morbid conditions.

• Reviva Pharmaceuticals Holdings, Inc. Reports Third Quarter 2022 Financial Results and Recent Business Highlights

  11/14/2022

  Reviva Pharmaceuticals Holdings, Inc. reported financial results for the third quarter ended September 30, 2022 and summarized recent business highlights.

• Reviva Pharmaceuticals Announces Global Enrollment Update for Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine for Schizophrenia

  10/31/2022

  Reviva Pharmaceuticals Holdings, Inc. today announced over 30% enrollment in the United States, and initiation and ongoing enrollment across sites in Europe for the pivotal Phase 3 RECOVER study evaluating brilaroxazine for the treatment of schizophrenia.

• Reviva Pharmaceuticals to Present at the Lytham Partners Fall 2022 Investor Conference

  9/26/2022

  Reviva Pharmaceuticals Holdings, Inc. announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the Lytham Partners Fall 2022 Investor Conference being held September 28–29, 2022 and invites investors to participate via virtual one-on-one meetings.